Drug Profile
Pembrolizumab companion diagnostic - Merck/NanoString Technologies
Latest Information Update: 22 Apr 2019
Price :
$50
*
At a glance
- Originator NanoString Technologies
- Developer Merck & Co; NanoString Technologies
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Cancer(Diagnosis) in World
- 28 May 2015 Clinical trials in Cancer (Diagnosis) in World (unspecified route)